Key facts
Latest information about our company.
Global business
Chief Executive Officer:
Headquarters:
Princeton, New Jersey, USA
Business:
Biopharmaceuticals
Web address:
NYSE listing:
BMY
Net global sales:
$45 billion in 2023
R&D investment:
$9.3 billion in 2023
Principal locations:
Local business
Australian head office:
Level 2, 4 Nexus Court,
Mulgrave, Victoria 3170
Australia
Mulgrave, Victoria 3170
Australia
Key products in market:
AZACTAM® (aztreonam)
CAMZYOS® (mavacamten)
ELIQUIS® (apixaban)
EMPLICITI® (elotuzumab)
EVOTAZ® (atazanavir & cobicistat)
ISTODAX® (romidepsin)
MONOPRIL® (fosinopril sodium)
ONUREG® (azacitidine)
OPDIVO® (nivolumab)
OPDUALAG™ (nivolumab/ relatlimab)
ORENCIA® (abatacept)
POMALYST® (pomalidomide)
REVLIMID® (lenalidomide)
REYATAZ® (atazanavir sulfate)
SOTYKTU™ (deucravacitinib)
SPRYCEL® (dasatinib)
THALOMID® (thalidomide)
VIDAZA® (azacitidine)
YERVOY® (ipilimumab)
ZEPOSIA™ (ozanimod)